Evidence map›Paper›PMID 36457126›Full record

ArticleJournal of neuroinflammation2022

An AGS-associated mutation in ADAR1 catalytic domain results in early-onset and MDA5-dependent encephalopathy with IFN pathway activation in the brain.

Xinfeng Guo, Richard A Steinman, Yi Sheng, Guodong Cao, Clayton A Wiley, Qingde Wang

Open access · goldAbstract read
In one paragraph

Article in Journal of neuroinflammation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Two codes of RNA editing by deamination in human diseases.Experimental & molecular medicine · 2026
    Review
  3. HeterozygousiScience · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. The role of ADAR1 in human pathophysiology.Frontiers in cell and developmental biology · 2025
    Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Xinfeng GuoDepartment of Surgery, University of Pittsburgh School of Medicine, 200 Lothrop Street, Pittsburgh, PA, 15213, USA.
Richard A SteinmanDepartment of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Yi ShengMagee Women Research Institute, University of Pittsburgh, Pittsburgh, PA, USA.
Guodong CaoDepartment of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Clayton A WileyDepartment of Pathology, School of Medicine, University of Pittsburgh, Scaife Hall, 200 Lothrop Street, Pittsburgh, PA, 15213, USA. wileyca@upmc.edu.
Qingde WangDepartment of Surgery, University of Pittsburgh School of Medicine, 200 Lothrop Street, Pittsburgh, PA, 15213, USA. wangqd@pitt.edu.
University of Pittsburgh · USMagee-Womens Research Institute · USVA Pittsburgh Healthcare System · US

Funding

White Matter Restoration in Vascular Cognitive Impairment and dementiaRF1NS117509 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CAO, GUODONG · 2020 to 2020
$2.2M
Role of the ADAR1-mediated RNA editing ∕ RNA sensing axis in sterile inflammationR01AI139544 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI WANG, QINGDE · 2019 to 2023
$1.9M
MicroRNA regulation of angiogenesis in agingI01RX001455 · VA · VETERANS HEALTH ADMINISTRATION · PI WANG, QINGDE · 2017 to 2022
–
BLRD VA I01 BX003923NIAID NIH HHS R01 AI139544NINDS NIH HHS RF1 NS117509RRD VA I01 RX001455
6 · The paper itself

Abstract

backgroundAicardi-Goutières syndrome (AGS) is a severe neurodegenerative disease with clinical features of early-onset encephalopathy and progressive loss of intellectual abilities and motor control. Gene mutations in seven protein-coding genes have been found to be associated with AGS. However, the causative role of these mutations in the early-onset neuropathogenesis has not been demonstrated in animal models, and the mechanism of neurodegeneration of AGS remains ambiguous.

methodsVia CRISPR/Cas-9 technology, we established a mutant mouse model in which a genetic mutation found in AGS patients at the ADAR1 coding gene (Adar) loci was introduced into the mouse genome. A mouse model carrying double gene mutations encoding ADAR1 and MDA-5 was prepared using a breeding strategy. Phenotype, gene expression, RNA sequencing, innate immune pathway activation, and pathologic studies including RNA in situ hybridization (ISH) and immunohistochemistry were used for characterization of the mouse models to determine potential disease mechanisms.

resultsWe established a mouse model bearing a mutation in the catalytic domain of ADAR1, the D1113H mutation found in AGS patients. With this mouse model, we demonstrated a causative role of this mutation for the early-onset brain injuries in AGS and determined the signaling pathway underlying the neuropathogenesis. First, this mutation altered the RNA editing profile in neural transcripts and led to robust IFN-stimulated gene (ISG) expression in the brain. By ISH, the brains of mutant mice showed an unusual, multifocal increased expression of ISGs that was cell-type dependent. Early-onset astrocytosis and microgliosis and later stage calcification in the deep white matter areas were observed in the mutant mice. Brain ISG activation and neuroglial reaction were completely prevented in the Adar D1113H mutant mice by blocking RNA sensing through deletion of the cytosolic RNA receptor MDA-5.

conclusionsThe Adar D1113H mutation in the ADAR1 catalytic domain results in early-onset and MDA5-dependent encephalopathy with IFN pathway activation in the mouse brain.

Indexed as

Brain InjuriesNeurodegenerative DiseasesAdenosine DeaminaseAnimalsAutoimmune Diseases of the Nervous SystemBrainCatalytic DomainDisease Models, AnimalMiceMutationNervous System MalformationsRNAADAR1 protein, mouseAdenosine DeaminaseRNAADAR1Aicardi–Goutières syndrome (AGS)Gene mutationInnate immunityMDA-5Mouse modelNeurodegenerationNeuroinflammationRNA sensing signaling pathway

Identifiers

PMID36457126
PMCPMC9714073
OpenAlexW4310522735

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.